This interview explores updated efficacy and safety findings from the phase 2 iMMagine-1 trial evaluating anito-cel, a CAR T-cell therapy, in patients with relapsed or refractory multiple myeloma, as ...
So normally the way we give CAR-T is that we take out the T-cells from patients, then we engineer them to attack them myeloma, and then we give them back to them. But that takes time because ...
– 96% Overall Response Rate, 74% Stringent Complete Response/Complete Response, and 95% Minimal Residual Disease Negativity Observed at a Median 15.9-months of Follow-up, with Responses Continuing to ...
Arcellx's anito-cel shows promising efficacy and safety in multiple myeloma, with a 97% response rate and low neurotoxicity, potentially differentiating it in a crowded market. Financially robust, ...
-- Results from all 117 patients dosed in the pivotal Phase 2 iMMagine-1 study of anito-cel demonstrated 97% ORR and 68% CR/sCR at a median follow-up of 12.6 months -- -- No delayed neurotoxicities ...
-- CAR constructs representative of anito-cel (D-Domain), cilta-cel (dual VHH), and ide-cel (scFv) were assessed preclinically for tonic signaling and off-target Claudin binding -- -- No tonic ...
Arcellx's anito-cel shows 97% overall response rate and 62% CR/sCR rate in high-risk RRMM patients during Phase 2 iMMagine-1 trial. No severe neurotoxicities observed in over 150 patients dosed, with ...
Gilead's other CAR-T therapies also performed poorly over the same period. In Q5 2025, Yescarta sold $368 million, down 6 ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Anitocabtagene autoleucel exhibited durable efficacy among heavily pretreated patients with ...
Mizuho Securities analyst Salim Syed has assigned their bullish stance on GILD stock, giving a Buy rating yesterday. Pick the best stocks and maximize your portfolio: Discover top-rated stocks from ...
-- Preliminary results from 86 patients enrolled in the Phase 2 pivotal iMMagine-1 study of anito-cel demonstrated 97% ORR and 62% CR/sCR at a median follow-up of 9.5 months -- -- No delayed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results